Navigation Links
AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
Date:9/24/2013

NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.

AbbVie and Galapagos will work collaboratively to contribute technologies and resources in order to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D.  The goal of the collaboration is to identify compounds that correct defects in expression of (corrector) and/or increase the activity (potentiator) of the main mutations in the cystic fibrosis transmembrane regulator (CFTR) protein, including the F508del mutation, which is the most common with 90 percent prevalence among patients with CF.

In the alliance, AbbVie and Galapagos will develop potentiators and correctors discovered by Galapagos and expand the range of molecules, with the aim to initiate Phase 1 clinical studies at the end of 2014.  Following successful clinical development and regulatory approval, AbbVie will be responsible for commercial activities, with Galapagos retaining exclusive rights in China and South Korea and co-promotion rights in Belgium, the Netherlands, and Luxembourg.  

Under the terms of the agreement, AbbVie will make an initial upfront payment of $45 million to Galapagos for rights related to the global alliance.  Upon successful completion of pre-determined success milestones, AbbVie and Galapagos will share responsibility and funding for Phase III clinical develo
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... Echo Therapeutics, Inc. (NASDAQ: ... skin permeation, continuous glucose monitoring and associated technologies, ... has been appointed Chief Executive Officer effective December ... years of experience in the medical device, pharmaceutical ... as Vice President, Business Development, Otsuka Pharmaceuticals as well ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... Healthcare Products Association (CHPA), representing makers of over-the-counter ... U.S. Food and Drug Administration (FDA) efforts to ... right amount of medicine. Today, the FDA,s Nonprescription ... enhancing the labels of all OTC single-ingredient pediatric ...
... 2011 Eli Lilly and Company (NYSE: LLY ... scientific and medical officer of the American Diabetes Association, has ... from his current role in late-July. In his ... for Lilly Diabetes in advocacy and clinical science communities and ...
Cached Medicine Technology:OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly 2David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly 3
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... But effect for women not same, as study cites obesity ... Vitamin K slows the development of insulin resistance in older ... resistance, a precursor to diabetes, occurs when the body cannot ... the blood. Overweight and obese people are prone to insulin ...
... 5 MetLife Mexico, Mexico City, Mexico, the largest ... a leading provider of such services to individual and ... Assist America, Inc., Princeton, N.J., the premier provider of ... 500,000 of its insureds with emergency travel assistance. ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... $0.185 per share on the company,s common stock, a ... per share. The dividend,is payable Dec. 31, 2008, to ... 17, 2008. Hillenbrand has paid quarterly dividends since its ...
... BlueShield today,announced that its employees committed more than $1 ... This amount is the,result of personal giving by ... Inc. , "In ... especially in need of help," said Mark Wagar, president ...
... heart problems, study says , , FRIDAY, Dec. 5 (HealthDay News) ... (IPF) are three times more likely than people without the ... attack, according to a British study. , "If you ... a threefold increased risk of acute coronary syndrome, which is ...
... 5 CANTEL MEDICAL CORP. (NYSE: ... diluted share, on a 7% increase in sales to $64,406,000 ... $0.02 of expenses related to the relocation of our Dutch ... income of $1,939,000, or $0.12 per diluted share, on sales ...
Cached Medicine News:Health News:Vitamin K Slows Insulin Resistance in Older Men 2Health News:MetLife Mexico Life Insurance Company Partners with Assist America for Global Emergency Medical Assistance Services 2Health News:Empire BlueCross BlueShield Associates Commit Over $1 Million to Community Organizations in 2008 2Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 3Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 4Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 5Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 6
... holes and additional electrode tip insulation, ... dissection with decreased risk of collateral ... ,Flexible design options allow the choice ... multiple tip designs. Optimize specific surgical ...
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: